- Home
- RCT vs IGMS Comparison
RCT vs IGMS Comparison
Compare RCT & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCT
- IGMS
- Stock Information
- Founded
- RCT 2014
- IGMS 1993
- Country
- RCT United Kingdom
- IGMS United States
- Employees
- RCT N/A
- IGMS N/A
- Industry
- RCT
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- RCT
- IGMS Health Care
- Exchange
- RCT NYSE
- IGMS Nasdaq
- Market Cap
- RCT 68.6M
- IGMS 82.1M
- IPO Year
- RCT 2025
- IGMS 2019
- Fundamental
- Price
- RCT $1.73
- IGMS $1.27
- Analyst Decision
- RCT Strong Buy
- IGMS Hold
- Analyst Count
- RCT 2
- IGMS 8
- Target Price
- RCT $5.00
- IGMS $6.14
- AVG Volume (30 Days)
- RCT 32.4K
- IGMS 173.6K
- Earning Date
- RCT 05-17-2025
- IGMS 05-13-2025
- Dividend Yield
- RCT N/A
- IGMS N/A
- EPS Growth
- RCT N/A
- IGMS N/A
- EPS
- RCT N/A
- IGMS N/A
- Revenue
- RCT $46,499,285.00
- IGMS $2,681,000.00
- Revenue This Year
- RCT N/A
- IGMS $124.45
- Revenue Next Year
- RCT N/A
- IGMS $45.07
- P/E Ratio
- RCT N/A
- IGMS N/A
- Revenue Growth
- RCT 134.76
- IGMS 27.36
- 52 Week Low
- RCT $1.23
- IGMS $0.92
- 52 Week High
- RCT $5.00
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- RCT N/A
- IGMS 52.80
- Support Level
- RCT N/A
- IGMS $1.13
- Resistance Level
- RCT N/A
- IGMS $1.42
- Average True Range (ATR)
- RCT 0.00
- IGMS 0.09
- MACD
- RCT 0.00
- IGMS 0.01
- Stochastic Oscillator
- RCT 0.00
- IGMS 55.88
About RCT REDCLOUD HOLDINGS PLC
RedCloud Holdings PLC developed and operate the RedCloud Platform, that facilitates the trading of everyday consumer supplies of fast-moving consumer goods (FMCG) products across business supply chains. The Platform solves old problem of how to unlock and enable access of key purchase and sales data between brands, distributors and retailers in growth consumer markets. Its Platform has AI and machine learning capabilities that provide brands, distributors and retailers with trading and product insights and data to help, make commercial decisions regarding their business operations. Geographically, Key revenue is generated from Nigeria.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.